Browsing by Author "Dogu M.H."

Now showing 1 - 7 of 7
  • No Thumbnail Available
    Item
    Clinical characteristics, post-treatment assessment and prognostic factors affecting patient survival of patients at 65 years of age or older with hodgkin lymphoma: A retrospective multicenter study from Turkey
    (A. CARBONE Editore, 2015) Berber I.; Erkurt M.A.; Keklik M.; Dogu M.H.; Terzi H.; Pala C.; Sari H.I.; Sencan M.; Sivgin S.; Hacioglu S.; Altuntas F.; Aydogdu I.; Ilhan O.
    Introduction: During the last three decades, major advances have been made in the therapy of Hodgkin's lymphoma. However, despite these advances, Hodgkin's lymphoma has a poor prognosis in the elderly. The proportion of Hodgkin's lymphoma patients aged > 60 ranges in the different reports between 15% and 35%. This study aimed to examine clinical characteristics, treatment outcomes and prognostic factors affecting patient survival in Hodgkin's lymphoma patients aged 65 years or older. Material methods: Hodgkin's lymphoma patients at 65 years of age and older managed within last 5 years in a total of 5 centers in Turkey were retrospectively assessed. Results: The median age of a total of 32 patients was 71 (65-83) years. Elderly patients presented more frequently with B symptoms, elevated sedimentation rate, mixed cellularity histologic subtype and comorbid disease. Less frequent were bulky disease, bone marrow involvement, and the application of autologous stem cell transplantation. The nodular lymphocyte predominant subtype and lymphocyte rich subtype were not observed at all. Eastern Cooperative Oncology Group, ferritin, total protein, and histological type were significant predictors affecting survival (p<0.05). Conclusions: Hodgkin's lymphoma is a more fatal disease in 65 years of age or older, when compared to the young population. Tumor biology, older age itself, and other factors related to comorbidity probably contribute to the worse outcome of elderly patients. Further large-scale studies are needed to better investigate the factors that were significant predictors of patient survival.
  • No Thumbnail Available
    Item
    Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: Twenty-four year Turkish experience in cladribine therapy
    (John Wiley and Sons Ltd, 2015) Hacioglu S.; Bilen Y.; Eser A.; Sivgin S.; Gurkan E.; Yildirim R.; Aydogdu I.; Dogu M.H.; Yilmaz M.; Kayikci O.; Tombak A.; Kuku I.; Celebi H.; Akay M.O.; Esen R.; Korkmaz S.; Keskin A.
    In this multicenter retrospective analysis, we aimed to present clinical, laboratory and treatment results of 94 patients with Hairy cell leukemia diagnosed in 13 centers between 1990 and 2014. Sixty-six of the patients were males and 28 were females, with a median age of 55. Splenomegaly was present in 93.5% of cases at diagnosis. The laboratory findings that came into prominence were pancytopenia with grade 3 bone marrow fibrosis. Most of the patients with an indication for treatment were treated with cladribine as first-line treatment. Total and complete response of cladribine was 97.3% and 80.7%. The relapse rate after cladribine was 16.6%, and treatment related mortality was 2.5%. Most preferred therapy (95%) was again cladribine at second-line, and third line with CR rate of 68.4% and 66.6%, respectively. The 28-month median OS was 91.7% in all patients and 25-month median OS 96% for patients who were given cladribine as first-line therapy. In conclusion, the first multicenter retrospective Turkish study where patients with HCL were followed up for a long period has revealed demographic characteristics of patients with HCL, and confirmed that cladribine treatment might be safe and effective in a relatively large series of the Turkish study population. © 2015 John Wiley & Sons, Ltd.
  • No Thumbnail Available
    Item
    Primary central nervous system lymphoma in daily practice and the role of autologous stem cell transplantation in relapsed disease: A retrospective multicenter study
    (Elsevier Ltd, 2016) Erkurt M.A.; Berber I.; Tekgündüz E.; Dogu M.H.; Korkmaz S.; Demir C.; Yilmaz M.; Akay O.M.; Pala C.; Bilen Y.; Kaya E.; Sari I.; Sencan M.; Kuku I.; Altuntaş F.; Dal M.S.; Aydogdu I.
    We investigated the course of 54 patients presenting with primary central nervous system lymphoma, who were treated in daily practice. The patients were treated with chemotherapy and/or radiotherapy and/or intrathecal chemotherapy. At a median follow-up period of 23 months (range 1-71), median relapse-free survival (RFS) and overall survival (OS) were not reached. Estimated 2-year RFS and OS rates were 42% and 48%, respectively. Ten relapsed PCNSL patients underwent ASCT. Complete remission rate of these patients was 40%, with 20% treatment-related mortality. Estimated 2-year RFS and OS rates were 37% and 40%, respectively. The prognosis of patients with PCNSL, who received off-study treatment, is still dismal. © 2016 Elsevier Ltd.
  • No Thumbnail Available
    Item
    Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience
    (John Wiley and Sons Ltd, 2018) Gemici A.; Aydogdu I.; Terzi H.; Sencan M.; Aslan A.; Kaya A.H.; Dal M.S.; Akay M.O.; Dogu M.H.; Ayyildiz O.; Sahin F.; Cagliyan G.A.; Yilmaz M.; Gokgoz Z.; Bilen Y.; Demir C.; Sevindik O.G.; Korkmaz S.; Eser B.; Altuntas F.
    Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey. We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty-three patients were included in the study. Median age of patients was 37.5 years (18-70) at the time of diagnosis. About 60.5% patients were diagnosed as stage I and II NLPHL, and remaining 39.5% had stage III and IV disease. Median follow-up was 46 months. During follow-up, none of the patients died. Seven patients relapsed or progressed after initial therapy at a median of 12 months. Five of 7 relapsed/refractory patients (71.4%) were salvaged with chemotherapy only (DHAP, ICE), and the remaining 2 (28.6%) were salvaged with chemoimmunotherapy. All of relapsed/refractory patients were able to achieve complete remission after salvage therapy. Lactate dehydrogenase levels were significantly higher in patients with progressive disease compared with nonprogressive disease. Our study showed an excellent outcome with all patients alive at last contact with a median follow up of 46 months despite a wide range of different therapeutic approaches. All relapsed and refractory patients were successfully salvaged despite a low frequency of patients received immunotherapy in conjunction with chemotherapy. Our results suggest that immunotherapy may be reserved for further relapses. Copyright © 2017 John Wiley & Sons, Ltd.
  • No Thumbnail Available
    Item
    Pralatrexate experience in peripheral T-cell lymphoma: A multicenter retrospective study from Turkey
    (Zerbinis Publications, 2021) Dal M.S.; Merdin A.; Erkurt M.A.; Ekinci Ö.; Albayrak M.; Hacıoglu S.K.; Kaya A.; Dogu M.H.; Hindilerden F.; Sarici A.; Merter M.; Aras M.R.; Caglıyan G.A.; Cakar M.K.; Aydogdu I.; Kuku I.; Korkmaz S.; Ulas T.; Eser B.; Altuntas F.
    Purpose: Pralatrexate is a new generation antifolate treatment agent used for the treatment of relapsed or refractory peripheral T-cell lymphomas. This study aims to determine the general characteristics of the patients receiving pralatrexate therapy in Turkey, contributing to the literature on the effectiveness of pralatrexate therapy in peripheral T-cell lymphomas by determining the response levels of such patients to the therapy. The study also attempts to clinically examine the major side effects observed in patients during treatment with pralatrexate. Methods: The study included patients with peripheral T-cell lymphoma followed up in the hematology units of several hospitals in Turkey. Overall, 20 patients aged 18 and over were included in the study. Results: The median age at the time of diagnosis was 58.5 years. PTCL-NOS (Peripheral T-cell lymphoma, not otherwise specified) subtype was in 40% of patients, making the PTCL-NOS the most common subtype in the study. In general, most patients were diagnosed with disease at an advanced stage. Pralatrexate therapy was given to the patients at a median treatment line of 3.5. Pralatrexate dose reduction was required in only 3 patients (15%). Response to pralatrexate therapy with partial remission (PR) and above was observed in 11 (55%) of the patients. Conclusion: Pralatrexate seemed to be a promising novel treatment in relapsed refractory PTCL patients. However, patients receiving pralatrexate should be followed up carefully for skin reactions, mucosal side effects, thrombocytopenia and neutropenia. © 2021 Zerbinis Publications. All rights reserved.
  • No Thumbnail Available
    Item
    The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
    (Elsevier Inc., 2022) Akpinar S.; Dogu M.H.; Celik S.; Ekinci O.; Hindilerden I.Y.; Dal M.S.; Davulcu E.A.; Tekinalp A.; Hindilerden F.; Ozcan B.G.; Hacibekiroglu T.; Erkurt M.A.; Bagci M.; Namdaroglu S.; Korkmaz G.; Bilgir O.; Cagliyan G.A.; Ozturk H.B.A.; Serin I.; Tiryaki T.O.; Ozatli D.; Korkmaz S.; Ulas T.; Eser B.; Turgut B.; Altuntas F.
    Introduction/Background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL in real-world settings. Patients/Methods: A total of 200 relapsed/refractory CLL patients with a median age of 68 were included in this retrospective, multicenter, non-interventional study. Data of the study were captured from the patient charts of the participating centers. Results: The median for lines of previous chemotherapy was 2 (1-6); 62 (31.8%) patients had del17p and/or p53 mutations (del17p+/p53mut). Of the study group, 146 (75%) patients achieved at least PR, while 16 (8.7%) patients discontinued ibrutinib due to TEA. The most common drug-related adverse events were neutropenia (n: 31; 17.4%) and thrombocytopenia (n: 40; 22.3%), which were ≥ grade 3 in 9 (5%) and 5 (3.9%) patients, respectively. Pneumonia (n: 42; 23.7%) was the most common nonhematologic TEA. Atrial fibrillation (n: 5; 2.8%) and bleeding (n: 11; 6.3%) were relatively rare during the study period. Within a median follow-up period of 17 (1-74) months, 42 (21%) patients died. The estimated median OS of the study cohort was 52 months. Only the response to ibrutinib (CR/PR vs. SD/PD) was significantly associated with OS. Conclusion: Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. © 2021 Elsevier Inc.
  • No Thumbnail Available
    Item
    Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey
    (Taylor and Francis Ltd., 2023) Bakırtaş M.; Dal M.S.; Yiğenoğlu T.N.; Giden A.O.; Serin I.; Başcı S.; Kalpakci Y.; Korkmaz S.; Ekinci O.; Albayrak M.; Basturk A.; Ozatli D.; Dogu M.H.; Hacıbekiroglu T.; Çakar M.K.; Ulas T.; Miskioglu M.; Gulturk E.; Eser B.; Altuntas F.
    A multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least ≥ two lines of therapy. Patients’ treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.5 ± 9.1 years. There were 20 patients (37.0%) with progression. Median progression-free survival was 13 months in patients who received a median of three therapy lines in a 7.5-month follow-up period. Overall response rate was 38.5%. Of 54 patients, 19 (40.4%) had at least one adverse event, and nine (19.1%) had an adverse event of at least grade 3 or more. Of 72 adverse events observed in 47 patients, 68% were grade 1 or 2. Treatment was not stopped in any patient due to adverse events. IRd combination therapy was effective and safe in heavily treated RRMM patients. © 2023 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia (Italian Society of Chemotherapy).